Literature DB >> 31088820

Yellow fever vaccine-associated neurological disease: it is not just the silver generation at risk.

Emily J Goldstein1, David J Bell2, Rory N Gunson1.   

Abstract

A 35-year-old man presented to his optician with sudden onset diplopia and a 1-week history of headaches. He was noted to have sixth nerve palsy. The following day he was admitted to hospital with confusion and expressive dysphasia. He had been due to travel to Ghana on business and had received yellow fever (YF) vaccination 18 days prior to onset of headaches. His initial cerebrospinal fluid (CSF) revealed elevated protein, increased white cell count but was PCR negative for standard viral pathogens. Herpes simplex virus (HSV)-1 was detected by PCR in CSF at a very low level from a second lumbar puncture performed 6 days later, and the patient was treated for HSV meningoencephalitis. However, retrospective investigation for yellow fever vaccine-associated neurological disease revealed increasing titres of YF IgG in three serial CSF samples, and no evidence of HSV antibodies in CSF or plasma, ruling out HSV encephalitis. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  infection (neurology); meningitis; vaccination/immunisation

Mesh:

Substances:

Year:  2019        PMID: 31088820      PMCID: PMC6536176          DOI: 10.1136/bcr-2019-229558

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

Review 1.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

Authors:  H Reiber; J B Peter
Journal:  J Neurol Sci       Date:  2001-03-01       Impact factor: 3.181

2.  Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-11-08       Impact factor: 17.586

3.  Intrathecal antibody production in two cases of yellow fever vaccine associated neurotropic disease in Argentina.

Authors:  Fanny Clara Pires-Marczeski; Valeria Paula Martinez; Corina Nemirovsky; Paula Julieta Padula
Journal:  J Med Virol       Date:  2011-12       Impact factor: 2.327

Review 4.  Specific diagnostic methods for herpesvirus infections of the central nervous system: a consensus review by the European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  A Linde; P E Klapper; P Monteyne; J M Echevarria; P Cinque; F Rozenberg; B F Vestergaard; M Ciardi; P Lebon; G M Cleator
Journal:  Clin Diagn Virol       Date:  1997-08

5.  The reemergence of yellow fever.

Authors:  Alan D T Barrett
Journal:  Science       Date:  2018-08-23       Impact factor: 47.728

6.  Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  J Erin Staples; Mark Gershman; Marc Fischer
Journal:  MMWR Recomm Rep       Date:  2010-07-30

7.  Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.

Authors:  Cristián Biscayart; María Eugenia Pérez Carrega; Sandra Sagradini; Angela Gentile; Daniel Stecher; Tomás Orduna; Silvia Bentancourt; Salvador García Jiménez; Luis Pedro Flynn; Gabriel Pirán Arce; María Andrea Uboldi; Laura Bugna; María Alejandra Morales; Clara Digilio; Cintia Fabbri; Delia Enría; Máximo Diosque; Carla Vizzotti
Journal:  Vaccine       Date:  2014-01-21       Impact factor: 3.641

8.  Yellow fever vaccine-associated neurotropic disease (YEL-AND) - A case report.

Authors:  Jolanta Florczak-Wyspiańska; Ewa Nawotczyńska; Wojciech Kozubski
Journal:  Neurol Neurochir Pol       Date:  2016-09-22       Impact factor: 1.621

9.  Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

Authors:  Ann W McMahon; Rachel B Eidex; Anthony A Marfin; Michelle Russell; James J Sejvar; Lewis Markoff; Edward B Hayes; Robert T Chen; Robert Ball; M Miles Braun; Martin Cetron
Journal:  Vaccine       Date:  2006-11-27       Impact factor: 3.641

10.  Short report: Incidence of yellow fever vaccine-associated neurotropic disease.

Authors:  Thomas Guimard; Sophie Minjolle; Elisabeth Polard; Fabien Fily; Hervé Zeller; Christian Michelet; Pierre Tattevin
Journal:  Am J Trop Med Hyg       Date:  2009-12       Impact factor: 2.345

View more
  2 in total

Review 1.  Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Authors:  Kay M Tomashek; Mark Challberg; Seema U Nayak; Helen F Schiltz
Journal:  Vaccines (Basel)       Date:  2019-11-08

Review 2.  A clinician's perspective on yellow fever vaccine-associated neurotropic disease.

Authors:  Elien Lecomte; Guy Laureys; Frederick Verbeke; Cristina Domingo Carrasco; Marjan Van Esbroeck; Ralph Huits
Journal:  J Travel Med       Date:  2020-11-09       Impact factor: 8.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.